As a promising biomarker, human epididymis protein 4 (HE4) has been widely used for the early detection and differential diagnosis of ovarian cancer. This study evaluated the function of HE4 in the carcinogenesis and progression of ovarian cancer. An enzyme immunometric assay, used to detect HE4 in the serum of ovarian cancer patients, showed that the protein could discriminate between malignant and benign ovarian tumours with high specificity. An exogenous HE4 gene was transfected into ovarian cancer cell lines and an immortalized ovarian epithelial cell line. Compared with the controls, HE4 overexpression significantly promoted cell apoptosis and adhesion. Overexpression of HE4 also led to significant inhibition of cell proliferation, migration and invasiveness in vitro, as well as xenograft tumour formation in vivo. This is the first report to demonstrate the functional importance of HE4 in multiple cellular processes and indicates that HE4 may play a protective role in the progression of ovarian cancer.
Introduction
Although ovarian cancer occurs with relatively low incidence in the general population (1.8%), 1 > 125 000 women worldwide die annually from this malignancy and it is responsible for more female deaths than all other gynaecological cancers combined. 2 Patients with early-stage organ-confined cancer (stage I) at diagnosis may have an overall survival approaching 93%. 1 Unfortunately, only approximately 20% of all reported cases are detected at this stage 3 due to the stealth nature of disease progression and the lack of a clinically validated screening method. 4 Human epididymis protein 4 (HE4) was first identified in the epithelium of the distal epididymis using Northern blot analysis and in situ transcript hybridization. 5, 6 HE4 is also referred to as WFDC2 because it contains two whey acidic protein (WAP) domains and a four-disulphide core comprising eight cysteine residues. Expression of the HE4 gene is highly restricted in normal human tissues, being largely limited to the respiratory epithelium of the proximal airways and the epithelium of the reproductive tracts 7, 8 and not expressed in normal ovarian surface epithelium (OSE). 7 In malignant neoplasms, a tumour-restricted pattern of upregulation L Gao, HY Cheng, L Dong et al.
HE4 in ovarian cancer makes HE4 a potential biomarker for various solid tumours such as ovarian cancer, 7, 9, 10 pulmonary adenocarcinoma, 11, 12 endometrial cancer, 13 mesothelioma 14 and breast cancer. 8 Over the past decade, HE4 has been used widely for the early screening 15, 16 and differential diagnosis 17, 18 of ovarian cancer, as well as for monitoring disease recurrence 19 and progression. 20 The HE4 promoter is also under investigation in terms of potential ovarian cancer gene therapy. 21 Multimarker panel studies with HE4 have shown better sensitivity and specificity in the detection of early-stage ovarian cancer and discrimination between benign and malignant cases. 22, 23 Our laboratory first reported the diagnostic value of HE4 in China 24 and then undertook a series of follow-up studies, 25, 26 the results of which were consistent with reports from other countries. 27, 28 Although the value of HE4 screening has been generally accepted, the role of HE4 in ovarian carcinoma is still undefined. To study gene function, researchers usually promote gene expression by gene transfection, or silence gene expression using RNA interference. Early work on HE4 expression in ovarian cancer cell lines by Drapkin et al. 7 showed that the ovarian serous adenocarcinoma cell line SKOV-3, the clear-cell carcinoma cell line ES-2, and the human telomerase-immortalized OSE cell line, contained either small amounts of HE4 protein or none at all. A recombinant plasmid containing the HE4 gene was used in the present study to transfect the SKOV-3, ES-2 and T29 cell lines (the latter being an immortalized human non-tumourigenic OSE cell line 29 ) in order to promote HE4 expression and explore its function, with the aim of furthering the clinical development of HE4 as a therapeutic target in the treatment of ovarian cancer.
Patients and methods

STUDY POPULATION
Consecutive patients with ovarian tumours were recruited, in the sequence of their surgery, from the Department of Obstetrics and Gynaecology at Peking University People's Hospital, Beijing, China, between January 2008 and December 2009. Healthy volunteers (controls) from the same geographical region as the patients were recruited in response to advertising. There were no other specific inclusion/exclusion criteria for the study.
After surgery, two pathologists categorized patients' tumour tissue samples as either benign or malignant in accordance with pathological diagnostic criteria for ovarian tumours. 30 The malignant tumour types were then subcategorized according to the World Health Organization classification. 31 Benign tumours were not subclassified by tumour type or location.
The study protocol was reviewed and approved by the Ethics Committee of Peking University and all patients were required to provide verbal informed consent before their samples were used in the study.
SPECIMEN COLLECTION AND HE4 MEASUREMENT
Serum samples were collected using a standard protocol under fasting conditions on the morning before operation and before any other tumour-related therapy. Serum samples were also obtained from the healthy volunteers (controls). Briefly, blood was collected in red-top Vacutainer™ tubes (no additives -Cat. No. 366430; Becton Dickinson, Franklin Lakes, NJ, USA) and left to clot for 60 -90 min before centrifuging for 10 min at 800 g. The serum fraction was removed and stored at −80°C until use.
Before the HE4 assay, the frozen specimens were thawed overnight at 4°C L Gao, HY Cheng, L Dong et al.
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and mixed thoroughly. Serum HE4 levels were quantified using a commercially available enzyme immunometric assay (EIA) (HE4 EIA Kit; Fujirebio Diagnostics, Gothenburg, Sweden). All procedures were performed according to the manufacturer's instructions and all quality controls were within the correct range. Protein quantitation was achieved by the construction of a standard curve using known concentrations of HE4 (provided with the commercial kit). Quantitative variables were reported as median values. A serum HE4 level > 150 pmol/l was defined as positive.
CELL LINES
The SKOV-3 and ES-2 cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37°C under 5% carbon dioxide and 95% relative humidity. The T29 cell line was cultured under the same conditions in a 1 : 1 mixture of MCDB105 and M199 media (Sigma-Aldrich, St Louis, MO, USA) with 15% FBS, 1% penicillin/streptomycin and 2 mM Lglutamine (Life Technologies, Gaithersburg, MD, USA).
CELL TRANSFECTION AND STABLE CELL LINE GENERATION
The T29, SKOV-3 and ES-2 cells were transfected with either the HE4 genecontaining recombinant plasmid, pIRES2-EGFP-HE4, or with the empty vector, pIRES2-EGFP, as a negative control (both from Invitrogen, Carlsbad, CA, USA). Transfection was carried out using Lipofectamine™ 2000 reagent (Invitrogen) according to the manufacturer's instructions. Stable derivatives were selected by treatment with Geneticin (G418; 400 µg/ml for ES-2 cells; 400 µg/ml for SKOV-3 cells; and 300 µg/ml for T29 cells) for 14 -18 days. Monoclones were selected by the 'limiting the dilution method'. Cells grown in medium without G418 were used as blank controls. Selected stably transfected cell lines were verified by amplification of the kanamycin/neomycin resistance gene (contained in the pIRES2-EGFP plasmid) by reverse transcriptionpolymerase chain reaction (RT-PCR). The RT-PCR was performed with the 2 × Taq PCR Master Mix Kit (Tiangen Biotech, Beijing, China) using the MJ Mini™ Personal Thermal Cycler (Bio-Rad, Hercules, CA, USA) according to the manufacturers' instructions. Primers for the kanamycin/neomycin resistance gene were: forward 5′ GGGACT GGCTGCTATTGG 3′ and reverse 5′-CCCGCT CAGAAGAACTCG-3′. Glyceraldehyde 3phosphate dehydrogenase (GAPDH) was used as the endogenous control with the following primers: forward 5′-GCTCACTG GCATGGCCTTCCG-3′ and reverse 5′-GTG GGCCATGAGGTCCACCAC-3′. The cycling programme involved preliminary denaturation at 94°C for 3 min, followed by 28 cycles of denaturation at 94°C for 30 s, annealing at 58°C for 30 s and elongation at 72°C for 60 s, followed by a final elongation step at 72°C for 5 min.
QUANTITATIVE REAL-TIME RT-PCR ANALYSIS OF HE4 GENE EXPRESSION
The T29, SKOV-3 and ES-2 cell lines stably transfected with the HE4 gene or empty vector, and untransfected controls, were grown to 80% confluence (approximately 48 -72 h) and harvested. Total RNA (1 × 10 7 cells/sample) was prepared using TRIzol ® reagent (Invitrogen), according to the manufacturer's instructions, followed by reverse transcription into cDNA using the Super RT Kit (Bioteke, Beijing, China). Quantitative real-time RT-PCR was based on original primers that specifically amplify 
WESTERN BLOT ANALYSIS OF HE4 GENE EXPRESSION
The T29, SKOV-3 and ES-2 cell lines stably transfected with the HE4 gene or empty vector, and untransfected controls, were grown to 80% confluence in serum-free medium for 72 h and then cell supernatants were harvested. To assess the levels of HE4 protein present in transfected cells and cell supernatants, whole-cell lysates were prepared in radioimmunoprecipitation assay lysis buffer (pH 7.4) with 1 × protease inhibitor cocktail (M221; Amresco, Solon, OH, USA). Samples containing equal amounts of protein were electrophoresed on 12% sodium dodecylsulphatepolyacrylamide gels and transferred onto polyvinylidene fluoride membranes (Millipore, Eschborn, Germany). The membranes were blocked overnight at 4°C in 1 × Tris-buffered saline with 0.1% Tween-20 (TBST), pH 7.4, and 5% non-fat dried milk, and then incubated sequentially with one of the primary antibodies, rabbit anti-HE4 (SIG-3731, 1 : 100 dilution; Covance Research Products, Emeryville, CA, USA) or rabbit anti-GAPDH (14C10, 1 : 1000 dilution; Cell Signaling Technology, Danvers, MA, USA), at room temperature for 1 h. The membranes were then washed three times with TBST to remove excess primary antibody and incubated with antirabbit secondary antibodies conjugated to horseradish peroxidase (ZB-2301, 1 : 10000 dilution;
Zhongshan Golden Bridge Biotechnology, Beijing, China) at room temperature for 1 h. The membranes were washed again three times with TBST and immunodetection was performed with the Super Electrochemiluminescence Detection System (Applygen Technologies, Beijing, China).
QUANTITATION OF SECRETED HE4 PROTEIN
The T29, SKOV-3 and ES-2 cell lines stably transfected with the HE4 gene or empty vector, and untransfected controls, were grown to 80% confluence (approximately 48 -72 h). The culture medium was then replaced with serum-free medium and the cells were incubated for an additional 72 h. The culture-conditioned medium was then harvested, concentrated and analysed using the HE4 EIA assay (described above) for quantitation of secreted HE4. The cell line with the maximum concentration of secreted HE4 and one of the cell lines with empty pIRES2-EGFP, chosen randomly, were selected and these cell clones were then used in subsequent experiments.
ASSESSMENT OF APOPTOSIS
To investigate the effect of HE4 on apoptosis in the selected T29, SKOV-3 and ES-2 cell L Gao, HY Cheng, L Dong et al.
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lines stably transfected with the HE4 gene or empty vector, and untransfected controls, dual-labelling analysis with Annexin Vphycoerythrin (PE)/7-amino-actinomycin (7-AAD) (BD Biosciences, San Diego, CA, USA) was performed. The cells were harvested and resuspended in residual liquid after rinsing with cold 10 mM phosphate-buffered saline (PBS; pH 7.4). Suspensions corresponding to 5 × 10 5 -1 × 10 6 cells were mixed with 5 µl Annexin V-PE and 5 µl of 7-ADD and then incubated at room temperature for 15 min away from light. Next, 400 µl of 1 × binding buffer (10 mM HEPES, 140 mM sodium chloride, 2.5 mM calcium chloride, pH 7.4) was added to each tube and the proportion of apoptotic cells was determined quantitatively by flow cytometry.
ASSESSMENT OF CELL PROLIFERATION
The effect of HE4 on cell proliferation was assessed by the Cell Counting Kit-8 (CCK-8; Dojindo Laboratories, Kumamoto, Japan) and soft agar colony assays. For the CCK-8 analysis, 3 × 10 3 cells from each of the selected T29, SKOV-3 and ES-2 cell lines stably transfected with the HE4 gene or empty vector, or untransfected controls, were seeded into each well of a 96-well plate in 100 µl of medium (1 : 1 mixture of MCDB105 and M199 media or RPMI medium, as appropriate, with 10% FBS) and preincubated overnight at 37°C under 5% carbon dioxide and 95% relative humidity. Then, 10 µl of CCK-8 solution was added to each well followed by incubation for 4 h. Absorbance was then measured at 450 nm using a microplate reader. To analyse proliferation over time, the CCK-8 assay was performed once every day for 4 -5 days in three independent experiments.
Anchorage-independent growth is a hallmark of cell proliferation. Thus, the growth of the different selected cell lines on soft agar was also measured. Parental or stably transfected cells (1000 cells) were suspended in 0.35% agar medium, plated in 6-cm plates coated with 0.6% agar and incubated at 37°C under 5% carbon dioxide and 95% relative humidity for 14 days. The cultures were analysed in triplicate and the number of colonies > 100 mm in diameter were counted.
IN VITRO ADHESION ASSAY
To assess in vitro cell adhesion, 50 µl of diluted Matrigel™ (BD Biosciences, San Jose, CA, USA; 1 : 4 dilution) was added to cover the bottom of 96-well plates followed by incubation at 37°C under 5% carbon dioxide and 95% relative humidity overnight. Subsequently, a 100-µl suspension of 1 × 10 4 cells of the SKOV-3 and ES-2 cell lines stably transfected with the HE4 gene or empty vector, or untransfected controls, were added to each well and incubated for 2 h. The number of cells adhering to the Matrigel™ was calculated indirectly using the CCK-8 assay (see above) according to the manufacturer's instructions.
IN VITRO MIGRATION AND INVASION ASSAY
Costar Transwell ® permeable chambers of 8µm pore size (Corning, Lowell, MA, USA) were used for the cell migration and invasion assay. A 100-µl cell suspension containing 1 × 10 5 cells of each of the SKOV-3 and ES-2 cell lines stably transfected with the HE4 gene or empty vector, or untransfected controls, was inoculated into the top layer of the chamber and 600 µl RPMI 1640 medium with 10% FBS was added into the bottom layer, in 24-well culture plates. After 24 h, the chambers were fixed in methanol and stained with crystal violet (0.1%). The number of cells 
STATISTICAL ANALYSES
All data were analysed using the SAS ® statistical software package, version 9.1 (SAS Institute Inc. Cary, NC, USA) for Windows ® .
The χ 2 -test was used for qualitative data analysis. Factorial-design analysis of variance (ANOVA) was used to test betweengroup differences for all in vitro analyses. One-way ANOVA was used for the in vivo experiment. A P-value < 0.05 was considered to be statistically significant.
Results
STUDY POPULATION
In total, 75 women with ovarian tumours provided both serum and tissue samples for this study. Serum samples were also obtained from 50 healthy volunteer controls. Following assessment of tissue samples from the patients 45 were categorized as benign and 30 as malignant. The malignant tumour group comprised 21 patients with epithelial ovarian cancers, four with ovarian germ-cell tumours, three with fallopian tube serous cancers and two with primary peritoneal carcinomas (newly diagnosed at the time of the study). The demographic characteristics of all three groups (benign, malignant and control) were similar (data not shown).
ANALYSIS OF HE4 IN SERUM SAMPLES
The results from the analysis of serum samples from the 75 patients with ovarian tumours and 50 healthy individuals are summarized in Table 1 . Analysis of the three groups demonstrated significantly higher levels of HE4 protein, assessed by EIA, in the malignant tumour versus the benign tumour group (P = 0.021) or the healthy control group (P = 0.029) ( Table 1) . None of the patients with benign tumours or the healthy individuals was positive (HE4 level > 150 pmol/l) for HE4 protein compared with 63.3% of the malignant tumour group (P < 0.0001).
IDENTIFICATION OF STABLY HE4 TRANSFECTED CELL LINES
Stably transfected cell lines were successfully created using the G418 selection and limiting dilution method. Using RT-PCR, cell lines transfected with pIRES2-EGFP-HE4 or pIRES2-EGFP showed steady-state mRNA levels for the kanamycin/neomycin resistance gene, even at the 15th passage L Gao, HY Cheng, L Dong et al.
HE4 in ovarian cancer ( Fig. 1) . Expression of the HE4 gene was determined by quantitative real-time RT-PCR, Western blot analysis and the HE4 EIA assay. Compared with the untransfected blank control, mean ± SD HE4 mRNA levels were 7475.81 ± 1901.38-fold, 12 368.36 ± 2386.61-fold and 3481.58 ± 296.22-fold higher in HE4-transfected cell lines (ES-2, T29 and SKOV-3, respectively), indicating that the exogenous HE4 gene had been integrated into the genome and was highly expressed. In the negative control group, levels of HE4 mRNA were similar to those seen in the blank control group ( Fig. 2A) . Western blot analysis (Fig. 2B) showed the expected HE4 protein bands in both the cell lysates and culture supernatants of cell lines transfected with exogenous HE4; HE4 bands were not detected in negative or blank control cells.
The HE4 EIA assay showed that mean ± SD levels of HE4 were not significantly different in the blank untransfected controls (ES-2, 5.26 ± 1.14 pM; T29, 6.26 ± 2.53 pM; SKOV-3, 8.55 ± 2.27 pM) or the 
HE4 AND APOPTOSIS
No significant difference was observed in the percentage of apoptotic cells between the blank untransfected and negative (empty vector) control cell lines, whereas the percentage of apoptosis was significantly higher in cells transfected with exogenous HE4 (P < 0.05 for SKOV-3; P < 0.01 for ES-2 and T29; Fig. 3 ). 
HE4 AND IN VITRO CELL PROLIFERATION
The CCK-8 findings showed no significant effect on cell proliferation within the limited observation time of the study for the HE4transfected cells compared with the blank untransfected and negative (empty vector) control cell lines (Fig. 4A) . In the soft-agar assay, no colonies were formed by any of the T29 group cells. The colony-forming ability of ES-2 or SKOV-3 negative control cells showed no significant changes compared with ES-2 or SKOV-3 untransfected cells, whereas HE4 transfection significantly reduced the number of colonies in both the ES-2 or SKOV-3 cell lines (P < 0.05; Fig. 4B ).
HE4 INFLUENCED TUMOUR METASTASIS IN VITRO
The adhesion assay demonstrated a significant increase in the number of adherent cells in the HE4 transfected groups compared with the controls for ES-2 and SKOV-3 cells (P < 0.05; Fig. 5A ). As shown in 
EFFECT OF HE4 ON XENOGRAFT MODEL
At 4 weeks postinoculation the growth of tumours formed by SKOV-3-HE4 transfected cells was significantly suppressed (P < 0.05; Fig. 6 ). The xenograft transplants gave rise to much smaller tumours than those from untransfected control cells; SKOV-3-HE4 tumours had a mean ± SD weight of 0.05 ± 0.02 g compared with 0.19 ± 0.11 g for SKOV-3 negative control tumours and 0.20 ± 0.14 g for SKOV3 untransfected tumours (P < 0.05, both comparisons). The significant effects of HE4 on the ES-2 groups are in line with observations in the SKOV-3 groups. HE4 decreased the weight of tumours induced by ES-2-HE4 transfected cells compared with both control groups (mean ± SD, ES-2-HE4 transfected, 0.34 ± 0.20 g; ES-2-negative Fig. 6 ). Neither the T29 HE4-transfected cells nor the control cells had measurable subcutaneous tumours at the end of the observation period.
Discussion
Ovarian cancer is a major cause of worldwide cancer-related mortality in women. 2 Consequently, there is a need for a clinically validated screening method for the detection of ovarian cancer to improve women's health.
Researchers have systematically evaluated the performance of a set of candidate markers to detect ovarian cancer. Of all the tumour markers currently being studied, HE4 is the most important because it can be used as a single marker. 32 The present study demonstrated that HE4 was overexpressed in ovarian cancers and distinguished women with, from women without, clinically apparent ovarian cancer. These findings, which were consistent with previous work by Hellström et al., 27 suggested that HE4 is a promising biomarker for distinguishing patients with malignant ovarian disease from those with benign ovarian tumours or healthy individuals.
As a robust tumour biomarker, the clinical contribution of HE4 is generally recognized, although the function of the HE4 protein remains unknown. Its roles in sperm maturation and antiproteinase activity within the male reproductive tract have been predicted, but no studies have been performed to confirm these functions. 5, 6 Another function involves its possible role in innate immunity. 33 No protease inhibitory activity has been identified for HE4. 12 In addition, many researchers think that HE4 may play an undefined role in carcinogenesis and tumour progression. 34 Whether HE4 is simply a biomarker for aggressive tumours or makes a functional contribution to tumour behaviour remains to be determined.
To our knowledge the present study is the first to analyse the function of HE4 in ovarian cancer. The study showed that HE4 expression induced significant apoptosis and has an essential role in regulating cell proliferation, inhibiting in vitro growth in the ES-2, SKOV-3 and T29 cell lines. Furthermore, introducing the HE4 gene into cancer cells dramatically inhibited cell metastatic ability and in vivo xenograft tumour formation. In light of these observations and data showing that HE4 may be a component in epithelial host defence 12 we propose a novel function of HE4 in ovarian cancer; i.e. its potential involvement in an antineoplastic mechanism.
The HE4 gene resides on human chromosome 20q12-13.1, which encodes a heterogeneous group of small acid-and heat-stable proteins that share homology with WAP. 35 Comparative genomic hybridization studies have shown the q12-13.1 locus on chromosome 20 is frequently amplified in gastric, oral, breast, ovarian, colon and pancreatic cancers. 36, 37 These findings led to the proposal that genes located in this region may play undefined roles in carcinogenesis and tumour progression. Four WAP-domain proteins (secretory leucocyte protease inhibitor [SLPI], elafin, WFDC2 and WFDC1) have been identified as candidate molecular markers for cancer. 34 Various studies have focused on the function of these WAP-domain proteins in cancer; some have reported a negative correlation between SLPI gene expression and tumour progression. 38 Specifically, the expression of SLPI is downregulated in cervical adenocarcinoma, which suggests an antitumourigenic function in some tissue types. 39 Because SLPI inhibits
• Received for publication 26 March 2011 • Accepted subject to revision 4 April 2011 • Revised accepted 2 September 2011 Copyright © 2011 Field House Publishing LLP lipopolysaccharide-induced activation of the nuclear factor κB (NFκB) pathway, 40 Hu et al. 38 speculated that SLPI expression might prevent breast carcinoma through inhibition of the NFκB pathway. The observation that WFDC1 inhibits the growth of PC-3 carcinoma cells points to the possibility that WFDC1 may affect prostatic carcinoma progression. A study on oncogenesis and tumour-suppressor genes showed that WFDC1 was downregulated by the src oncogene, lending further support to the proposal that WFDC1 is a tumour-suppressor gene. 41 Moreover, data from Li and Sarkar 42 and Liang et al. 43 also suggested that elafin expression and the immortal growth of cancer cells or transformed cells might be mutually exclusive. In conclusion, these studies have suggested that WAP-domain proteins are antitumourigenic, which is consistent with the results reported here for HE4.
Many WAP-domain proteins, including SLPI and elafin, are proteinase inhibitors: they counteract environmental proteolytic conditions that promote tumour progression. 44 Thus, as a member of the WAP-domain protein family, it could be speculated that HE4 may have a similar functional role. Expression of HE4 was upregulated in some cell lines in the present study, then the tumour cells took advantage of the antiproteinase function of HE4 to prevent the degradation of surrounding tissues caused by tumour-secreted proteinases, resulting in prolonged progression-free survival.
In summary, the current preliminary study demonstrated the functional importance of HE4 in multiple cellular processes. This is the first direct evidence showing the possible association of HE4 with antitumour progression. Although the underlying antineoplastic mechanism of HE4 in ovarian cancer requires further investigation and validation, these findings provide a direction for exploring a therapeutic target for ovarian cancer.
